Abstract
A pro-drug is a substance administered in a pharmacologically inactive structure that, once administered, is metabolised in vivo into the corresponding active principle. The rationale for the design of prodrugs is the optimisation of absorption, distribution, metabolism, and excretion (ADME). Moreover these compounds are frequently synthesized to improve bioavailability. 5-Amino salicylic acid (5-ASA) represents one of the most efficient agents for ColoRectal Cancer (CRC) treatment. Its inclusion in natural or semi-synthetic cyclodextrins (CDs) has been extensively studied to enhance drug properties as solubility, stability, and bioavailability. On the other hand, very recently naturally occurring 4'-geranyloxyferulic acid and auraptene were found as novel promising agents for the treatment of colon diseases, like adenomas and adenocarcinomas. In this review we will focus our attention on the reported pharmacological activity and analytical assays for the most representative 5-ASA pro-drugs already in a therapy for the treatment of CRC and on novel prodrugs of 4'-geranyloxyferulic acid and auraptene that were shown to be efficient in vivo as dietary feeding colon cancer chemopreventers in mice.
Keywords: CRC, IBD, inclusion compounds, 4'-geranyloxyferulic acid, auraptene, biological activity, analytical method, HPLC-UV/Vis methodologies, pro-drug, b-cyclodextrin
Current Drug Delivery
Title: Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays
Volume: 9 Issue: 2
Author(s): Francesco Epifano, Salvatore Genovese, Giuseppe Carlucci and Marcello Locatelli
Affiliation:
Keywords: CRC, IBD, inclusion compounds, 4'-geranyloxyferulic acid, auraptene, biological activity, analytical method, HPLC-UV/Vis methodologies, pro-drug, b-cyclodextrin
Abstract: A pro-drug is a substance administered in a pharmacologically inactive structure that, once administered, is metabolised in vivo into the corresponding active principle. The rationale for the design of prodrugs is the optimisation of absorption, distribution, metabolism, and excretion (ADME). Moreover these compounds are frequently synthesized to improve bioavailability. 5-Amino salicylic acid (5-ASA) represents one of the most efficient agents for ColoRectal Cancer (CRC) treatment. Its inclusion in natural or semi-synthetic cyclodextrins (CDs) has been extensively studied to enhance drug properties as solubility, stability, and bioavailability. On the other hand, very recently naturally occurring 4'-geranyloxyferulic acid and auraptene were found as novel promising agents for the treatment of colon diseases, like adenomas and adenocarcinomas. In this review we will focus our attention on the reported pharmacological activity and analytical assays for the most representative 5-ASA pro-drugs already in a therapy for the treatment of CRC and on novel prodrugs of 4'-geranyloxyferulic acid and auraptene that were shown to be efficient in vivo as dietary feeding colon cancer chemopreventers in mice.
Export Options
About this article
Cite this article as:
Epifano Francesco, Genovese Salvatore, Carlucci Giuseppe and Locatelli Marcello, Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays, Current Drug Delivery 2012; 9 (2) . https://dx.doi.org/10.2174/156720112800234549
DOI https://dx.doi.org/10.2174/156720112800234549 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Mucoadhesive Formulation Designs for Oral Controlled Drug Release at the Colon
Current Pharmaceutical Design Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Polyphenol Supplementation as a Complementary Medicinal Approach to Treating Inflammatory Bowel Disease
Current Medicinal Chemistry Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety The Epigenetic Origin of Aneuploidy
Current Genomics Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry Estrogens and Colorectal Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Studying the Human Gut Microbiota in the Trans-Omics Era - Focus on Metagenomics and Metabonomics
Current Pharmaceutical Design Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity
Current Drug Metabolism Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery